A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Clinical Trial ID NCT01639001

Rank	Title	Journal	Year	PubWeight™‹?›
1	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.	J Cancer	2013	1.31
2	Review of the current targeted therapies for non-small-cell lung cancer.	World J Clin Oncol	2014	1.05
3	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.	J Thorac Oncol	2015	0.97
4	Medical management of lung cancer: Experience in China.	Thorac Cancer	2015	0.94
5	Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib.	Onco Targets Ther	2015	0.90
6	ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.	Transl Lung Cancer Res	2014	0.89
7	Recent advances in personalized lung cancer medicine.	Per Med	2014	0.82
8	MET inhibitors in combination with other therapies in non-small cell lung cancer.	Transl Lung Cancer Res	2012	0.78
9	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.	BMC Cancer	2016	0.78
10	ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.	Oncotarget	2016	0.76